Experienced in Pancreaticoduodenectomy

Dr. Lon S. Schneider

Psychiatry
1520 San Pablo St, Ste 1652, 
Los Angeles, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Pancreaticoduodenectomy
1520 San Pablo St, Ste 1652, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lon Schneider is a Psychiatrist in Los Angeles, California. Dr. Schneider is rated as an Experienced provider by MediFind in Pancreaticoduodenectomy. His top areas of expertise are Alzheimer's Disease, Dementia, Menopause, Vascular Dementia, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 238 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Pancreaticoduodenectomy.

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO

Locations

1520 San Pablo St, Ste 1652, Los Angeles, CA 90033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Enrollment Status: Recruiting
Publish Date: November 21, 2024
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Development of Novel Measures of Cognition and Function for Alzheimer's Disease Prevention Trials
Development of Novel Measures of Cognition and Function for Alzheimer's Disease Prevention Trials
Enrollment Status: Suspended
Publish Date: May 18, 2025
Intervention Type: Other
Study Phase: Not Applicable
Escitalopram for Agitation in Alzheimer's Disease
Escitalopram for Agitation in Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Escitalopram
Study Phase: Phase 3
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Drug
Study Drug: Solanezumab
Study Phase: Phase 3
Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)
Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Drug
Study Drug: Prazosin
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1
Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1
Enrollment Status: Completed
Publish Date: July 05, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

238 Total Publications

Response to Letter to the Editor "Comments on 'Novel Non-Linear Models for Clinical Trial Analysis With Longitudinal Data: A Tutorial Using SAS for Both Frequentist and Bayesian Methods'".
Response to Letter to the Editor "Comments on 'Novel Non-Linear Models for Clinical Trial Analysis With Longitudinal Data: A Tutorial Using SAS for Both Frequentist and Bayesian Methods'".
Journal: Statistics in medicine
Published: August 26, 2025
Similar Doctors
Experienced in Pancreaticoduodenectomy
Dr. Sung Hyon
Psychiatry
Experienced in Pancreaticoduodenectomy
Dr. Sung Hyon
Psychiatry

Kaiser Permanente Pasadena Medical Offices

3280 E Foothill Blvd, 
Pasadena, CA 
 (9.1 miles away)
833-574-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sung Hyon is a Psychiatrist in Pasadena, California. Dr. Hyon is rated as an Experienced provider by MediFind in Pancreaticoduodenectomy. His top areas of expertise are Post-Traumatic Stress Disorder (PTSD), Schizophrenia, Schizoaffective Disorder, Bipolar Disorder (BPD), and Pancreaticoduodenectomy. Dr. Hyon is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schneider's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile